The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Hypersensitivity skin reactions in melanoma patients treated with vemurafenib after ipilimumab therapy.
James J. Harding
No relevant relationships to disclose
Mario E. Lacouture
Consultant or Advisory Role - Amgen; AVEO; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; ImClone Systems; Onyx; OSI Pharmaceuticals; Pfizer; Roche/Genentech
Honoraria - Amgen; AVEO; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; ImClone Systems; Onyx; OSI Pharmaceuticals; Pfizer; Roche/Genentech
Research Funding - GlaxoSmithKline
Melissa Pulitzer
No relevant relationships to disclose
Margaret Callahan
Research Funding - Bristol-Myers Squibb
Michael Andrew Postow
No relevant relationships to disclose
Richard D. Carvajal
Consultant or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Paul B. Chapman
Consultant or Advisory Role - GlaxoSmithKline; Roche/Genentech
Research Funding - GlaxoSmithKline; Roche/Genentech